Status:
UNKNOWN
ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or
Lead Sponsor:
University Hospital, Brest
Conditions:
Advanced Hepatocellular Carcinoma
Eligibility:
All Genders
18-99 years
Brief Summary
Evaluation of the efficacy and safety of the combination ATEZOLIZUMAB - BEVACIZUMAB in the treatment of locally advanced inoperable or metastatic hepatocellular carcinoma in Finistère
Detailed Description
Patients treated by ATEZOLIZUMAB and BEVACIZUMAB for an Advanced hepatocellular carcinoma will be followed to observed their safety and the efficacy of this treatment, and to identify prongnosis facto...
Eligibility Criteria
Inclusion
- hepatocellular carcinoma locally advanced or metastatic, non able to be resectable, with no prior systemic treatment
- Child Pugh A and ECOG 0 or 1
- upper digestiuve endoscopy less than 6 months, if esophageal varcices : must be treated
- non eligible to receive a locoregional therpay or progressive after this kinf of treatment
- with informed consent
Exclusion
- refuse to participate
- under legal protection
- exclusion criteria from the tempory utilisation authorization
Key Trial Info
Start Date :
January 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 18 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04730388
Start Date
January 18 2021
End Date
January 18 2022
Last Update
January 29 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.